Products

Fludeoxyglucose F 18 Injection

(Available in Puerto Rico only)

Fludeoxyglucose F 18 injection (FDG F 18) is an injectable radiopharmaceutical used for diagnostic purposes in positron emission tomography (PET) imaging procedures in the oncology, cardiology and neurology settings.

FDG F 18 is used in oncology for the assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.

FDG F 18 is used in cardiology for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.

FDG F 18 is used in neurology for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. PET published data indicates that PET imaging helps physicians often change their intended management of patients with known cancer.

Puerto Rico

Lantheus MI Radiopharmaceuticals, Inc
150 Federico Costa , Suite 1
San Juan, PR 00918-1303

Sales

Phone: 787-765-5598 Ext: 2502

Important Safety Information

INDICATIONS AND USAGE

Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:

  • Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
  • Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
  • Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

IMPORTANT SAFETY INFORMATION

Radiation Risks
Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.

Blood Glucose Abnormalities
In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F 18 Injection administration.

Adverse Reactions
Hypersensitivity reactions with pruritus, edema and rash have been reported; have emergency resuscitation equipment and personnel immediately available.

Please see full Prescribing Information.

Ordering Information

Customer Service

Phone: 787-765-5598 Ext: 2504
Email: cs-pr@lantheus.com
Fax: 787-763-4032

EDoseConnect

www.edoseconnect.com

This information is intended for US customers. Approved labeling and indications vary by country. Please call customer service at 787-765-5598 Ext: 2504 for more information.